Olink Proteomics Acquires Agrisera AB

AVS Bio Acquires ImmunoPrecise Antibodies (Europe) B.V.

August 6, 2025

Biotechnology

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V., a carve-out from ImmunoPrecise Antibodies Ltd. The acquisition expands AVS Bio's European footprint and adds antibody discovery, recombinant protein expression, and organoid growth factor development capabilities to its biologics services platform.

Thermo Fisher Scientific Acquires Olink Holding AB

July 10, 2024

Biotechnology

Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.

Rovensa Acquires Agro-K

December 5, 2023

Agriculture

Rovensa Group has acquired Agro-K, a family-owned U.S. biostimulants developer founded in 1976 and based in Minneapolis. Agro-K will be integrated into Rovensa Next to strengthen Rovensa's biosolutions portfolio and accelerate its expansion in the United States; financial terms were not disclosed.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Rovensa Acquires Oro Agri, Inc.

January 21, 2021

Agriculture

Lisbon-based Rovensa has acquired Oro Agri, Inc., a Fresno, California-based leader in bio-rational crop protection and adjuvant technology. The deal expands Rovensa's product portfolio and helps establish a stronger presence in North America while combining marketing, sales and R&D capabilities across the combined businesses.

Summa Equity Acquires Olink Proteomics

March 13, 2019

Biotechnology

Summa Equity has acquired a majority stake in Olink Proteomics (Olink AB), a Uppsala-based life science company specializing in proteomics and protein biomarker discovery. The transaction is financed with senior secured/unitranche financing provided by EQT Credit and will support Olink's global scaling and continued product and service development.